Subscribe to Search results

Hazel Blears, Parliamentary Under-Secretary of State for Public Health, was "keen to see a detailed (self-sufficiency) report as soon as possible."

Published on:

Katie Scott

Published on:

Inquiry publishes timetable for final oral submissions

Published on:

Inquiry publishes expert report on childhood bereavement

Published on:

Supplementary letter on virology issued to Hepatitis expert group

Published on:

Dr Owen expressed his belief that the NHS should have been self-sufficient to have made the "best-known treatment more readily available to people suffering from haemophilia."

Published on:

Professor Garrott Allen (Stanford University) expressed his concern to Dr Maycock (Consultant Advisor, CMO) about commercial blood products being purchased by Britain from the United States.

Published on:

Granada screened its "World in Action programme Blood Money - Part 1" documentary in the UK.

Published on:

Granada screened "World in Action programme Blood Money - Part 2" documentary in the UK.

Published on:

Reverend Tanner (Chair, Haemophilia Society) met Dr Owen and described that he "spoke very forcibly to Dr David Owen to let him know that [he was] not prepared to accept the risk of hepatitis coming from the blood products issued from the United States."

Published on:

At a Haemophilia Society meeting, it was discussed that "Dr Owen stated that in 1977 we would be fully self-sufficient in concentrates. The whole question of commercial concentrates, plasmapheresis, the regional structure of the BTS, and other matters were fully discussed."

Published on:

A DHSS meeting minutes recorded Dr Owen stressing "his personal commitment to self-sufficiency".

Published on:

Dr Owen took Dr Maycock's advice on his criticism of the regional structure of the blood transfusion service which was recorded in Department of Health minutes.

Published on:

Dr John Cash wrote to the BMJ stating, "There is no doubt that the import into the United Kingdom of factor VIII concentrates derived from external sources, however well screened for hepatitis viruses, represents an unequivocal pathway by which the level of a potentially lethal infection into the whole community is being deliberately increased."

Published on:

Dr Cooper (Assistant Secretary for US Health, Department of Health, Education and Welfare) commented: "We feel that the warning is quite direct and adequate; in fact, it is generally appreciated in the U.S. that every lot of this particular product is probably contaminated with hepatitis B virus."

Published on:

Dr Diana Walford stated that "if somebody applied to the Medicines Division or the licensing authority, as they actually were deemed, for a clinical trial certificate or a clinical trial exemption certificate that was to be considered. It fell to be considered by Medicines Division, whether it needed to go entirely to a Committee on Safety of Medicines Meeting I think might have depended on the product."

Published on:

It appeared that there was no site examination at any of the blood collection centres in the USA.

Published on:

Dr Diana Walford recalled that upon visiting a USA manufacturing facility, the inspector and herself were very unhappy due to the lack of hygiene among other things.

Published on:

At the Haemophilia Reference Centre Directors meeting it was suggested the implication was that the cheaper (Kryobulin produced in the US) product carried the higher risk of plasma viral hepatitis which worried some Directors.

Published on:

It was mentioned at the Haemophilia Reference Centre Directors meeting that the European (red) material was still available for those who felt it carried a lower risk of conveying hepatitis, although both were equally safe.

Published on: